Baricitinib (Figure 1A), a selective and reversible JAK1 and JAK2 inhibitor, is commonly used to treat moderate to severe active RA in adult patients with poor response to one or more tumor necrosis factor inhibitors (TNFis) [7]. The gene discussed is TNF; the disease is rheumatoid arthritis.